1. Home
  2. EXFY vs ENTX Comparison

EXFY vs ENTX Comparison

Compare EXFY & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expensify Inc.

EXFY

Expensify Inc.

HOLD

Current Price

$2.32

Market Cap

156.2M

Sector

Technology

ML Signal

HOLD

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$2.89

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXFY
ENTX
Founded
2008
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
156.2M
147.4M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
EXFY
ENTX
Price
$2.32
$2.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$4.50
$9.00
AVG Volume (30 Days)
1.1M
3.6M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.22
Revenue
$142,101,000.00
$42,000.00
Revenue This Year
$0.42
N/A
Revenue Next Year
$0.11
N/A
P/E Ratio
N/A
$13.05
Revenue Growth
2.06
N/A
52 Week Low
$0.69
$0.91
52 Week High
$2.81
$4.20

Technical Indicators

Market Signals
Indicator
EXFY
ENTX
Relative Strength Index (RSI) 62.10 57.95
Support Level $1.32 $1.10
Resistance Level N/A $3.22
Average True Range (ATR) 0.20 0.32
MACD 0.02 -0.05
Stochastic Oscillator 51.42 13.81

Price Performance

Historical Comparison
EXFY
ENTX

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app. Small and medium-sized businesses (SMBs) are the cornerstone of the global economy, making up almost all businesses and the majority of employment in Organization for Economic Co-operation and Development (OECD) member countries.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: